戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 as an initiating event in the development of clear-cell renal carcinoma.
2 l in individual patients with organ-confined clear-cell renal carcinoma.
3 hypermethylation, is also common in sporadic clear cell renal carcinomas.
4 he development of the malignant phenotype of clear cell renal carcinomas.
5 ) disease and is implicated in most sporadic clear cell renal carcinomas.
6 e at risk of developing multiple independent clear cell renal carcinomas.
7 n Hippel-Lindau disease and in most sporadic clear cell renal carcinomas.
8 nic anhydrase-IX, which is over-expressed in clear-cell renal carcinomas.
9 evelopment of sporadic hemangioblastomas and clear-cell renal carcinomas.
10 ion of vascular endothelial growth factor by clear-cell renal carcinomas.
11 ectrum of malignant neoplasms: conventional (clear cell) renal carcinoma (11 of 11 cases), transition
12 ET with (124)I-cG250 can identify accurately clear-cell renal carcinoma; a negative scan is highly pr
13 eficient cell lines and tumors, specifically clear cell renal carcinomas and hemangioblastomas.
14 nd central nervous system hemangioblastomas, clear cell renal carcinomas and pheochromocytomas.
15                       Inherited and sporadic clear cell renal carcinomas are characterized by inactiv
16                                              Clear cell renal carcinomas are the most common form of
17 s inactivated in both sporadic and inherited clear cell renal carcinoma associated with VHL disease.
18                                           In clear cell renal carcinoma (CCRC), hypoxic signaling is
19  XBSeq2 by using a set of in-house generated clear cell renal carcinoma (ccRCC) samples.
20 is an archetypical tumor-initiating event in clear cell renal carcinoma (ccRCC) that leads to the act
21 ed the anti-tumor effect of MLN4924 in human clear cell renal carcinoma (ccRCC).
22 in VHL disease, congenital polycythaemia and clear cell renal carcinoma (ccRCC).
23  encode E3 ubiquitin (Ub) ligases mutated in clear-cell renal carcinomas (ccRCC).
24                                         Most clear cell renal carcinomas (ccRCCs) are initiated by so
25                                              Clear cell renal carcinomas (ccRCCs) can display intratu
26 s mutated in diverse tumour types, including clear cell renal carcinomas (ccRCCs).
27 HL) disease tumor suppressor gene in a human clear cell renal carcinoma cell line, UOK 121, that cont
28             Complementation of VHL-defective clear cell renal carcinoma cell lines with wild-type VHL
29 nducible factor (HIF)-2alpha in VHL-positive clear cell renal carcinoma cells phenocopied loss of VHL
30 t seemed to selectively target VHL-deficient clear cell renal carcinoma cells.
31 rt a case of a 56-year-old male patient with clear cell renal carcinoma confirmed on a histopathologi
32 Lindau gene inactivation is observed in most clear cell renal carcinoma, driving the malignant phenot
33 the loss of the VHL tumor suppressor gene in clear cell renal carcinoma for potential clinical benefi
34 e inactivated in VHL disease and in sporadic clear-cell renal carcinomas, has recently been shown to
35 se, small mitochondria have been observed in clear cell renal carcinomas known to have frequent VHL a
36 al-cord hemangioblastomas, retinal angiomas, clear-cell renal carcinoma, neuroendocrine tumors and cy
37 mours were histopathologically classified as clear-cell renal carcinoma or otherwise.
38                                   Late-stage clear cell renal carcinoma poses a formidable clinical c
39 nd in the majority of patients with sporadic clear cell renal carcinoma (RCC).
40 Introduction of wild type VHL transgene into clear cell renal carcinoma restored low level expression
41 e are also found in the majority of sporadic clear cell renal carcinoma, the most common malignant ne
42 dy chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressi
43 1a in seven cases and pT1b in one case (five clear cell renal carcinoma, two chromophobe type, and on
44         Sixty-three patients with metastatic clear-cell renal carcinoma were treated with bevacizumab
45 ntral nervous system, pheochromocytomas, and clear cell renal carcinoma, which result from somatic in
46 X antigen, has shown the potential to target clear cell renal carcinoma with high sensitivity and spe

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。